5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist
psilocybin for smoking cessation. Three sites with experience in conducting psilocybin
research will be involved in this trial: Johns Hopkins University (JHU), the University of
Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66
participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in
session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and
either 150 mg or 200 mg in session 2), with sessions 1 week apart.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
National Institute on Drug Abuse (NIDA) New York University University of Alabama at Birmingham